Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S002 - Melanoma and Mimics: New Diagnostic and Treatment Modalities

Friday, February 16; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize the morphology and molecular pathology of different melanoma sub-types and borderline lesions.
  • Determine the appropriate patient management algorithm based on the combination of clinico-pathological correlation and, if necessary, molecular findings.
  • Discuss the newly available molecular tests and the new treatment options for metastatic melanoma such as targeted therapy, immunotherapy, and combination therapies.

Description

This session will consist of a combination of formal lectures and interactive presentations. Different melanoma types and borderline melanocytic lesions will be discussed with emphasis on a combined approach spanning from clinico-pathological presentation to new molecular techniques available for diagnosis. New treatment options will also be discussed including targeted therapy and immunotherapy. The session will be directed to general Dermatologists, Dermato-oncologists, and Dermatopathologists. The participants will be actively engaged through ARS.

Disclosures

  • Hoang, Mai, MD: no financial relationships exist with commercial interests.
  • Mihm, Martin Charles Jr., MD: Alnylam – C(IP); BioCoz – A(NC); Caliber Imaging and Diagnostics Inc. – A(NC); MelaSciences – A(NC); Novartis – C(IP); Wiley & Sons, Inc. – C(IP);
  • Piris, Adriano, MD: no financial relationships exist with commercial interests.
  • Sullivan, Ryan, MD: Amgen – A(Fees); Array BioPharma – C(Fees); Biodesix, Inc. – A(Fees); Boehringer Ingelheim – O(Fees); Genentech, Inc. – C(Fees); Merck & Co., Inc – A(Fees); Novartis – A(Fees); Replimmune – A(Fees); Syndax Pharmaceuticals – A(Fees); WorldCare Clinical LLC – C(Fees);
  • Wargo, Jennifer, MD: Bristol-Myers Squibb – SP(H); Dava Oncology – SP(H); Genentech, Inc. – A(H); GlaxoSmithKline – A(H); Illumina, Inc. – SP(H); Imedex, LLC – SP(H); Microbiome DX – O(NC); Novartis – A(H); Roche Laboratories – A(H);
  • Zakka, Labib, MD: no financial relationships exist with commercial interests.
Schedule
Friday, February 16
9:00 AM
Dr. Mihm / Atypical Melanocytic Proliferations, Diagnosis and Treatment
9:45 AM
Dr. Piris / Primary Cutaneous Melanoma, Morphology and Classification
10:15 AM
Dr. Zakka / The AJCC Staging System For Cutaneous Melanoma, 8th Edition
10:35 AM
Dr. Sullivan / The Role Of BRAF targeted Therapy In The Immunotherapy Era
11:05 AM
Wargo / Update on Adjuvant Therapy in Melanoma
11:35 AM
Dr. Hoang / Cutaneous Side Effects In Targeted Therapy and Immunotherapy
11:55 AM
All faculty / Panel Discussion And Questions
Event Details
  • Date
    Friday, February 16
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 5A
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Martin Charles Mihm Jr., MD, FAAD
Speakers
  • Adriano Piris, MD
  • Jennifer Wargo, MD
  • Labib Zakka, MD
  • Mai Hoang, MD
  • Ryan Sullivan, MD